- Supported exchanges /
- TWO /
- 4147.TWO
TaiMed Biologics (4147 TWO) stock market data APIs
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. It develops and markets Ibalizumab (TMB-355) Intravenous Infusion, a humanized monoclonal antibody for the treatment of HIV-1 infection. It is also developing TMB-355 Intravenous Push, a humanized monoclonal antibody for the treatment of HIV-1 infection; TMB-355 Intramuscular Injection, a humanized monoclonal antibody intramuscular injection, which is in Phase III clinical trials for treating HIV-1; TMB-365, an anti-CD4 recombinant humanized monoclonal antibody, which completed Phase I clinical trials for treating HIV infections; and TMB-365/TMB-380, a neutralizing HIV-1 antibody. The company was incorporated in 2007 and is headquartered in Taipei, Taiwan.
TaiMed Biologics Financial Data Overview
| 80.6 | |
| 78 | |
| - | |
| 81.4 | |
| 77.6 | |
| 66.6-116.5 | |
| 21 983 M | |
| 273 M | |
| 642 M | |
| -0.1 | |
| 0.318 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
TaiMed Biologics Fundamental Data is available in our Financial Data APIs
- Net Revenue 642 M
- EBITDA 39 777 K
- Earnings Per Share -0.42
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get TaiMed Biologics Earnings via APIs
- Latest Release 2024-08-08
- EPS/Forecast -0.06
Get TaiMed Biologics End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
